Rehovot, Israel

Anna Balanov

USPTO Granted Patents = 7 

 

Average Co-Inventor Count = 3.9

ph-index = 2

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2009-2012

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Anna Balanov

Introduction

Anna Balanov is a prominent inventor based in Rehovot, Israel. She has made significant contributions to the field of pharmaceuticals, particularly in the preparation and purification of important compounds. With a total of seven patents to her name, Balanov's work has had a substantial impact on the industry.

Latest Patents

Among her latest patents, Balanov has developed processes for the preparation and purification of gabapentin enacarbil. This compound is synthesized from intermediates such as 1-haloalkyl carbamate or carbonate and diacid acetal skeleton. The process involves combining a C1 to C4 alcohol or C1 to C4 primary amine with a solvent selected from various groups, including acetonitrile and hydrocarbons. Additionally, she has worked on the development of rosuvastatin and its salts, focusing on reducing alkylether impurities in the final product.

Career Highlights

Balanov is currently employed at Teva Pharmaceutical Industries Limited, a leading global pharmaceutical company. Her innovative work has contributed to the advancement of drug formulations and has positioned her as a key figure in her field.

Collaborations

Throughout her career, Anna Balanov has collaborated with notable colleagues, including Natalia Shenkar and Valerie Niddam-Hildesheim. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Anna Balanov's contributions to pharmaceutical innovation are noteworthy, with her patents reflecting her expertise and dedication to improving drug formulations. Her work continues to influence the industry and pave the way for future advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…